2Raymond E, Buquet - Fagot C, Djellu S, et al. Antitumor activity of oxaliplatin in combination with 5 - fluorourail and the thymidylate synthase inhibitor AG337 in human colon, breast,and ovarian cancers[J]. Anticancer Druges, 1997,8, 876.
3De Gramont,Figer A,Seymour M,et al. Leucovorin and fluorouracil with or without oxaliplatin as first - line treatment in advanced colorectal cancer[J]. J Clin Oncol,2000,18:2938.
5Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
6Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.
7Misset JL. Oxaliplatin in practice [ J ] . Br J Cancer, 1998, 77(Suppl 4):S4- S7.
8Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin; a critical review[ J ] . Clin Cancer Res ,2000,6(4) : 1205 - 1218.
9Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspeets[J]. Clin Pharmacokinet,2000,38(1) : 1 - 21.
10Luo FR, Wyrick SD, Charley SG. Biotransformations of oxaliplatin in rat blood in vitro[J] .J Biochem Mol Toxicol ,1999 ,13(3-4):159- 169.
